Rajesh Jaganath, MD
Cardiovascular Disease (Cardiology) · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 2
- 2 carriers
- Offices
- 11
Offices
11 locations · Sutter Bay Medical Foundation · Physician Services at El Camino Hospital
Looking this up.
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
2 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Jaganath’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
2 of 2 plans
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A119670 · Current
Licensed to practise in California · since 2012 · expires 2028-01-31 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$293,951
Medicare paid this office $293,951 for 1,649 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 352 | $70,072 | $111 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 201 | $39,077 | $187 |
| Long return visit (40+ min) | 120 | $31,364 | $163 |
| Mri scan of heart before and after contrast | 65 | $24,893 | $377 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 79 | $15,508 | $103 |
See all 36 services
| Return visit (30+ min) | 352 | $70,072 | $111 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 201 | $39,077 | $187 |
| Long return visit (40+ min) | 120 | $31,364 | $163 |
| Mri scan of heart before and after contrast | 65 | $24,893 | $377 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 79 | $15,508 | $103 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 50 | $10,534 | $211 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 146 | $8,665 | $58 |
| New patient visit (60+ min) | 42 | $8,351 | $199 |
| Ct scan of blood vessels and grafts of heart with contrast | 29 | $8,130 | $280 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 490 | $6,297 | $12 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 14 | $6,195 | $442 |
| Critical care, first 30-74 minutes | 12 | $5,632 | $182 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 254 | $4,937 | $15 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $3,718 | $143 |
| Ultrasound of heart with probe in esophagus, with report | 39 | $3,692 | $90 |
| Programming of dual lead pacemaker system | 34 | $3,029 | $74 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 345 | $2,940 | $7 |
| New patient visit (45+ min) | 18 | $2,817 | $157 |
| Injection, gadobutrol, 0.1 ml | 65 | $2,780 | $0 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 44 | $2,428 | $22 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 16 | $2,363 | $76 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 29 | $2,203 | $73 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 37 | $2,174 | $24 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 31 | $1,953 | $63 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 76 | $1,624 | $21 |
| Heart rhythm recording of continous external ekg over 8-15 days | 75 | $938 | $12 |
| Ambulatory blood pressure monitoring, 1 day or longer, with recording, scanning analysis, interpretation, and report | 21 | $823 | $39 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 37 | $784 | $20 |
| Ultrasound of heart blood flow, valves and chambers | 37 | $590 | $15 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 37 | $504 | $13 |
| Electrocardiogram (ecg) 2-day continuous | 16 | $306 | $19 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 29 | $276 | $0 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 16 | $249 | $16 |
| Injection, regadenoson, 0.1 mg | 16 | $151 | None |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 37 | $103 | $3 |
| 3d radiographic procedure | 12 | $102 | $9 |
Who their Medicare patients are
1,649 Original Medicare patients in 2024. Average age 78 · Under 65 2% · 85 and older 23% · Women 52% · Also on Medicaid 14% · Health risk score 1.33. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 39% · Atrial fibrillation 34% · Diabetes 29% · Chronic kidney disease 28% · Heart failure 26% · Cancer 21% · Depression 18% · COPD 12% · Stroke 12% · Dementia 11%.
The office billed $1,419,844, Medicare allowed $395,579 and paid $293,951; for 17,731 services of 58 kinds; $3,212 of it was for drugs given in the office and $290,739 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,649 | 17,731 | 78 | 1.33 | $1,419,844 | $293,951 |
| 2023 | 1,621 | 11,238 | 78 | 1.38 | $1,269,834 | $287,731 |
| 2022 | 1,542 | 7,920 | 78 | 1.40 | $1,246,306 | $303,620 |
| 2021 | 1,714 | 7,448 | 78 | 1.33 | $1,281,462 | $311,161 |
| 2020 | 1,584 | 4,749 | 77 | 1.43 | $1,059,267 | $258,455 |
| 2019 | 1,723 | 3,342 | 77 | 1.34 | $1,010,472 | $238,369 |
| 2018 | 1,333 | 2,335 | 77 | 1.42 | $653,045 | $163,944 |
| 2017 | 285 | 425 | 76 | 1.14 | $121,909 | $33,151 |
| 2014 | 11 | 14 | 66 | 3.61 | $7,714 | $1,613 |
| 2013 | 11 | 11 | 71 | 0.91 | $7,429 | $1,492 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 34 services
| Return visit (30+ min) | 363 | $67,157 | $110 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 134 | $26,580 | $195 |
| Long return visit (40+ min) | 110 | $23,224 | $160 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 77 | $19,787 | $108 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 36 | $17,280 | $480 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 73 | $16,216 | $222 |
| Mri scan of heart before and after contrast | 34 | $13,573 | $399 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 178 | $11,512 | $62 |
| New patient visit (60+ min) | 51 | $10,117 | $198 |
| Critical care, first 30-74 minutes | 21 | $8,656 | $192 |
| Ct scan of blood vessels and grafts of heart with contrast | 28 | $8,355 | $298 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 48 | $8,156 | $157 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 466 | $6,044 | $12 |
| Injection, regadenoson, 0.1 mg | 30 | $5,355 | None |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 34 | $5,083 | $75 |
| Programming of dual lead pacemaker system | 39 | $4,938 | $78 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 59 | $3,811 | $65 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 356 | $3,202 | $7 |
| Ultrasound of heart with probe in esophagus, with report | 27 | $2,389 | $88 |
| New patient visit (45+ min) | 13 | $1,876 | $144 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 78 | $1,860 | $23 |
| Injection, gadobutrol, 0.1 ml | 36 | $1,422 | $0 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 14 | $1,134 | $76 |
| Heart rhythm recording of continous external ekg over 8-15 days | 78 | $1,053 | $13 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 32 | $889 | $23 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 25 | $744 | $26 |
| Ambulatory blood pressure monitoring, 1 day or longer, with recording, scanning analysis, interpretation, and report | 14 | $653 | $47 |
| Electrocardiogram (ecg) 2-day continuous | 29 | $583 | $20 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 29 | $479 | $17 |
| Ultrasound of heart blood flow, valves and chambers | 25 | $378 | $15 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 29 | $286 | $0 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 11 | $217 | $20 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 11 | $135 | $12 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 18 | $46 | $3 |
2022: 33 services
| Return visit (30+ min) | 382 | $80,999 | $113 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 188 | $39,877 | $202 |
| Long return visit (40+ min) | 86 | $21,132 | $166 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 37 | $17,849 | $482 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 67 | $14,825 | $94 |
| Mri scan of heart before and after contrast | 34 | $14,012 | $412 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 57 | $11,692 | $180 |
| Analysis of data from ct study of heart blood vessels to assess severity of heart artery disease, with interpretation and report | 12 | $10,651 | $888 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 40 | $9,319 | $233 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 141 | $8,981 | $62 |
| New patient visit (60+ min) | 42 | $8,570 | $204 |
| Ct scan of blood vessels and grafts of heart with contrast | 24 | $6,933 | $289 |
| Injection, regadenoson, 0.1 mg | 34 | $6,478 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 473 | $6,198 | $13 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 35 | $6,055 | $86 |
| Critical care, first 30-74 minutes | 15 | $4,848 | $194 |
| Programming of dual lead pacemaker system | 39 | $4,226 | $75 |
| Ultrasound of heart with probe in esophagus, with report | 37 | $3,689 | $97 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 56 | $3,363 | $60 |
| New patient visit (45+ min) | 18 | $2,745 | $152 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 293 | $2,533 | $7 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 78 | $1,957 | $24 |
| Heart rhythm recording of continous external ekg over 8-15 days | 78 | $1,236 | $15 |
| Short return visit (20+ min) | 12 | $971 | $65 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 28 | $891 | $22 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 23 | $745 | $23 |
| Injection, gadobutrol, 0.1 ml | 18 | $697 | $0 |
| Ultrasound of heart blood flow, valves and chambers | 33 | $551 | $16 |
| Electrocardiogram (ecg) 2-day continuous | 26 | $512 | $19 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 26 | $426 | $16 |
| 3d radiographic procedure | 23 | $205 | $9 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 23 | $178 | $0 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 34 | $99 | $3 |
2021: 29 services
| Return visit (30+ min) | 381 | $83,290 | $113 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 181 | $38,478 | $203 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 51 | $26,635 | $522 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 92 | $21,642 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 78 | $14,826 | $179 |
| Ct scan of blood vessels and grafts of heart with contrast | 47 | $14,297 | $304 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 177 | $11,654 | $64 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 46 | $10,984 | $239 |
| Long return visit (40+ min) | 60 | $10,373 | $157 |
| New patient visit (45+ min) | 56 | $8,399 | $150 |
| Injection, regadenoson, 0.1 mg | 44 | $8,279 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 601 | $8,138 | $13 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 43 | $7,704 | $90 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 80 | $4,970 | $61 |
| Programming of dual lead pacemaker system | 41 | $4,407 | $79 |
| Analysis of data from ct study of heart blood vessels to assess severity of heart artery disease, with interpretation and report | 20 | $3,430 | $171 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 303 | $3,044 | $8 |
| New patient visit (60+ min) | 13 | $2,612 | $201 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 94 | $2,309 | $24 |
| Ultrasound of heart with probe in esophagus, with report | 21 | $2,051 | $98 |
| Heart rhythm recording of continous external ekg over 8-15 days | 94 | $1,562 | $16 |
| Short return visit (20+ min) | 21 | $1,455 | $66 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 34 | $1,172 | $25 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 30 | $878 | $22 |
| Electrocardiogram (ecg) 2-day continuous | 36 | $694 | $19 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 36 | $581 | $16 |
| Ultrasound of heart blood flow, valves and chambers | 21 | $355 | $17 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 44 | $352 | $0 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 22 | $64 | $3 |
2020: 26 services
| Return visit (30+ min) | 309 | $53,745 | $91 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 155 | $32,833 | $204 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 85 | $27,930 | $97 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 52 | $26,911 | $518 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 81 | $17,096 | $188 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 173 | $12,068 | $67 |
| New patient visit (45+ min) | 66 | $9,417 | $143 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 612 | $9,076 | $14 |
| Injection, regadenoson, 0.1 mg | 45 | $8,073 | None |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 43 | $7,874 | $89 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 31 | $7,267 | $234 |
| Long return visit (40+ min) | 50 | $6,815 | $134 |
| Ct scan of blood vessels and grafts of heart with contrast | 15 | $4,721 | $315 |
| Programming of dual lead pacemaker system | 47 | $3,670 | $56 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 58 | $3,506 | $60 |
| Telephone medical discussion with physician, 11-20 minutes | 38 | $2,736 | $68 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 265 | $2,671 | $8 |
| External ekg recording for more than 48 hours up to 21 days | 85 | $2,150 | $25 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 85 | $1,894 | $22 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 33 | $982 | $23 |
| Electrocardiogram (ecg) 2-day continuous | 36 | $862 | $24 |
| Analysis of data from ct study of heart blood vessels to assess severity of heart artery disease, with interpretation and report | 17 | $812 | $48 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 36 | $780 | $22 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 25 | $665 | $22 |
| Ambulatory blood pressure monitoring, 1 day or longer, with recording, scanning analysis, interpretation, and report | 12 | $393 | $33 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 12 | $85 | $0 |
2019: 28 services
| Return visit (30+ min) | 269 | $53,060 | $95 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 182 | $38,543 | $205 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 55 | $27,713 | $504 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 77 | $19,794 | $90 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 60 | $13,289 | $221 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 60 | $12,418 | $180 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 152 | $10,478 | $66 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 681 | $10,420 | $15 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 42 | $7,316 | $87 |
| Injection, regadenoson, 0.1 mg | 36 | $6,487 | None |
| New patient visit (45+ min) | 40 | $5,510 | $138 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 76 | $4,638 | $61 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 358 | $3,321 | $8 |
| Programming of dual lead pacemaker system | 33 | $2,983 | $60 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 13 | $2,385 | $95 |
| External ekg recording for more than 48 hours up to 21 days | 62 | $1,606 | $25 |
| New patient visit (30+ min) | 15 | $1,530 | $102 |
| Long return visit (40+ min) | 11 | $1,503 | $137 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 62 | $1,455 | $23 |
| Ultrasound of heart with probe in esophagus, with report | 13 | $1,422 | $95 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,270 | $98 |
| Electrocardiogram (ecg) 2-day continuous | 44 | $1,169 | $26 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 45 | $1,050 | $23 |
| Analysis of data from ct study of heart blood vessels to assess severity of heart artery disease, with interpretation and report | 19 | $869 | $46 |
| Injection of drug or substance into vein | 17 | $683 | $40 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 13 | $380 | $24 |
| Ultrasound of heart blood flow, valves and chambers | 14 | $257 | $16 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 14 | $45 | $3 |
2018: 20 services
| Return visit (30+ min) | 139 | $26,371 | $99 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 115 | $24,377 | $203 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 37 | $18,982 | $513 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 58 | $12,819 | $221 |
| New patient visit (45+ min) | 89 | $12,541 | $141 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 58 | $11,135 | $91 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 133 | $8,615 | $64 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 532 | $8,136 | $15 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 43 | $8,112 | $180 |
| Injection, regadenoson, 0.1 mg | 28 | $4,965 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 69 | $4,052 | $59 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 24 | $3,920 | $87 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 15 | $2,867 | $96 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 310 | $2,717 | $8 |
| Long return visit (40+ min) | 12 | $1,543 | $129 |
| External ekg recording for more than 48 hours up to 21 days | 40 | $1,164 | $28 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 40 | $1,005 | $24 |
| Electrocardiogram (ecg) 2-day continuous | 27 | $767 | $28 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 27 | $662 | $25 |
| Programming of dual lead pacemaker system | 11 | $631 | $53 |
2017: 9 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 29 | $6,423 | $221 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 15 | $4,136 | $276 |
| New patient visit (45+ min) | 22 | $3,344 | $152 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $3,085 | $93 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 162 | $2,659 | $16 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,357 | $181 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 35 | $2,022 | $56 |
| Return visit (30+ min) | 13 | $1,621 | $101 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 12 | $806 | $67 |
Medicaid work
$2,223 in 2024
Medicaid paid $2,223 for 340 billed services this clinician did in 2024, up to 120 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 286 | $1,342 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 54 | $882 |
| 2024 | 340 | 2 | 120 | $2,223 |
| 2023 | 352 | 4 | 105 | $5,188 |
| 2022 | 241 | 3 | 91 | $2,007 |
| 2021 | 242 | 3 | 87 | $1,541 |
| 2020 | 184 | 3 | 68 | $2,393 |
| 2019 | 209 | 2 | 79 | $1,477 |
| 2018 | 190 | 2 | 58 | $2,057 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 66 | $1,932 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 19 | $1,719 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 238 | $1,168 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 29 | $370 |
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 186 | $991 |
| Return visit (30+ min) | 40 | $893 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 15 | $124 |
2021
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 167 | $705 |
| Return visit (30+ min) | 47 | $435 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 28 | $401 |
2020
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 16 | $1,033 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 27 | $777 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 141 | $584 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 38 | $774 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 171 | $703 |
2018
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 75 | $1,728 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 115 | $329 |
Drugs they prescribed that Part D paid
$1,139,326
Pharmacies billed $1,139,326 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 5,033) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
4,229 generic and 804 brand-name prescriptions · $1,139,326 in drug cost · 28 antibiotic prescriptions to 14 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 481 | $708,021 | $1,472 |
| Entresto | 85 | $104,312 | $1,227 |
| Jardiance | 70 | $96,558 | $1,379 |
| Repatha Sureclick | 49 | $73,039 | $1,491 |
| Xarelto | 48 | $64,771 | $1,349 |
See all 39 drugs
| Eliquis | 481 | $708,021 | $1,472 |
| Entresto | 85 | $104,312 | $1,227 |
| Jardiance | 70 | $96,558 | $1,379 |
| Repatha Sureclick | 49 | $73,039 | $1,491 |
| Xarelto | 48 | $64,771 | $1,349 |
| Metoprolol | 591 | $10,903 | $18 |
| Atorvastatin | 521 | $5,087 | $10 |
| Losartan | 349 | $4,490 | $13 |
| Ezetimibe | 141 | $4,256 | $30 |
| Rosuvastatin | 263 | $4,202 | $16 |
| Amlodipine Besylate | 441 | $3,683 | $8 |
| Isosorbide Dinitrate | 21 | $2,846 | $136 |
| Diltiazem 24hr Er (Cd) | 76 | $2,726 | $36 |
| Flecainide Acetate | 74 | $2,684 | $36 |
| Amiodarone | 125 | $2,063 | $17 |
| Lisinopril | 169 | $1,890 | $11 |
| Furosemide | 252 | $1,828 | $7 |
| Bumetanide | 31 | $1,666 | $54 |
| Valsartan | 58 | $1,502 | $26 |
| Hydralazine | 97 | $1,475 | $15 |
| Digoxin | 70 | $1,453 | $21 |
| Carvedilol | 125 | $1,369 | $11 |
| Torsemide | 30 | $1,285 | $43 |
| Clopidogrel | 76 | $1,230 | $16 |
| Eplerenone | 17 | $1,024 | $60 |
| Isosorbide Mononitrate Er | 54 | $1,020 | $19 |
| Metoprolol | 111 | $992 | $9 |
| Bisoprolol | 16 | $892 | $56 |
| Olmesartan Medoxomil | 44 | $875 | $20 |
| Pantoprazole | 38 | $827 | $22 |
| Hydrochlorothiazide | 112 | $718 | $6 |
| Spironolactone | 73 | $675 | $9 |
| Doxazosin Mesylate | 34 | $541 | $16 |
| Nifedipine Er | 15 | $329 | $22 |
| Pravastatin | 16 | $274 | $17 |
| Atenolol | 44 | $267 | $6 |
| Simvastatin | 22 | $220 | $10 |
| Amoxicillin | 24 | $115 | $5 |
| Nitroglycerin | 11 | $92 | $8 |
Year by year
| 2024 | 5,033 | 560 | 0% (0) | 16% | $1,139,326 |
| 2023 | 4,348 | 550 | 0% (0) | 14% | $942,036 |
| 2022 | 4,288 | 513 | 0% (0) | 14% | $789,159 |
| 2021 | 3,655 | 494 | 0% (0) | 15% | $637,013 |
| 2020 | 2,624 | 401 | 0% (0) | 16% | $407,314 |
| 2019 | 1,464 | 271 | 0% (0) | 16% | $163,578 |
| 2018 | 647 | 112 | 0% (0) | 17% | $54,505 |
| 2017 | 34 | 17 | 0% (0) | None | $2,749 |
| 2015 | 13 | None | 0% (0) | None | $555 |
| 2014 | 90 | 18 | None | 28% | $22,411 |
| 2013 | 34 | None | None | None | $980 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 37 drugs
| Eliquis | 413 | $625,571 | $1,515 |
| Entresto | 55 | $79,061 | $1,437 |
| Xarelto | 38 | $58,777 | $1,547 |
| Repatha Sureclick | 22 | $39,012 | $1,773 |
| Jardiance | 13 | $24,428 | $1,879 |
| Metoprolol | 551 | $14,818 | $27 |
| Isosorbide Dinitrate | 18 | $14,701 | $817 |
| Losartan | 360 | $7,780 | $22 |
| Atorvastatin | 483 | $7,024 | $15 |
| Ezetimibe | 137 | $5,973 | $44 |
| Diltiazem 24hr Er (Cd) | 91 | $4,952 | $54 |
| Amlodipine Besylate | 384 | $4,745 | $12 |
| Rosuvastatin | 184 | $4,554 | $25 |
| Flecainide Acetate | 65 | $4,414 | $68 |
| Valsartan | 53 | $2,770 | $52 |
| Furosemide | 244 | $2,574 | $11 |
| Digoxin | 59 | $2,296 | $39 |
| Amiodarone | 71 | $2,256 | $32 |
| Carvedilol | 119 | $2,040 | $17 |
| Hydralazine | 75 | $1,994 | $27 |
| Lisinopril | 153 | $1,896 | $12 |
| Isosorbide Mononitrate Er | 43 | $1,589 | $37 |
| Torsemide | 34 | $1,477 | $43 |
| Bumetanide | 14 | $1,290 | $92 |
| Eplerenone | 16 | $1,256 | $78 |
| Metoprolol | 93 | $872 | $9 |
| Spironolactone | 67 | $866 | $13 |
| Clopidogrel | 48 | $844 | $18 |
| Hydrochlorothiazide | 108 | $810 | $8 |
| Bisoprolol | 17 | $675 | $40 |
| Doxazosin Mesylate | 31 | $553 | $18 |
| Atenolol | 41 | $399 | $10 |
| Pantoprazole | 30 | $397 | $13 |
| Pravastatin | 23 | $327 | $14 |
| Nitroglycerin | 19 | $305 | $16 |
| Simvastatin | 16 | $176 | $11 |
| Amoxicillin | 23 | $31 | $1 |
2022: 37 drugs
| Eliquis | 409 | $527,250 | $1,289 |
| Xarelto | 41 | $54,980 | $1,341 |
| Entresto | 38 | $54,171 | $1,426 |
| Repatha Sureclick | 21 | $26,870 | $1,280 |
| Metoprolol | 469 | $12,739 | $27 |
| Praluent | 13 | $12,590 | $968 |
| Ezetimibe | 145 | $7,421 | $51 |
| Rosuvastatin | 163 | $7,256 | $45 |
| Atorvastatin | 432 | $5,935 | $14 |
| Isosorbide Dinitrate | 33 | $5,832 | $177 |
| Flecainide Acetate | 60 | $5,729 | $95 |
| Valsartan | 52 | $4,921 | $95 |
| Losartan | 314 | $4,640 | $15 |
| Diltiazem 24hr Er (Cd) | 78 | $4,406 | $56 |
| Amlodipine Besylate | 373 | $3,893 | $10 |
| Hydralazine | 101 | $3,820 | $38 |
| Amiodarone | 91 | $3,309 | $36 |
| Torsemide | 60 | $3,061 | $51 |
| Furosemide | 267 | $2,553 | $10 |
| Isosorbide Mononitrate Er | 55 | $2,005 | $36 |
| Digoxin | 52 | $2,001 | $38 |
| Carvedilol | 113 | $1,497 | $13 |
| Clopidogrel | 65 | $1,380 | $21 |
| Lisinopril | 152 | $1,331 | $9 |
| Spironolactone | 89 | $1,228 | $14 |
| Metoprolol | 103 | $1,044 | $10 |
| Pantoprazole | 38 | $978 | $26 |
| Bisoprolol | 11 | $832 | $76 |
| Hydrochlorothiazide | 114 | $805 | $7 |
| Dilt-Xr | 11 | $640 | $58 |
| Atenolol | 55 | $604 | $11 |
| Clonidine | 22 | $498 | $23 |
| Pravastatin | 30 | $445 | $15 |
| Benazepril | 14 | $246 | $18 |
| Ramipril | 12 | $196 | $16 |
| Simvastatin | 18 | $163 | $9 |
| Amoxicillin | 25 | $37 | $1 |
2021: 37 drugs
| Eliquis | 356 | $434,777 | $1,221 |
| Xarelto | 36 | $45,564 | $1,266 |
| Entresto | 25 | $36,676 | $1,467 |
| Metoprolol | 401 | $12,584 | $31 |
| Rosuvastatin | 173 | $7,178 | $41 |
| Praluent | 11 | $6,297 | $572 |
| Atorvastatin | 292 | $5,134 | $18 |
| Diltiazem 24hr Er (Cd) | 83 | $4,875 | $59 |
| Flecainide Acetate | 54 | $4,826 | $89 |
| Ezetimibe | 82 | $4,324 | $53 |
| Isosorbide Dinitrate | 17 | $4,235 | $249 |
| Losartan | 212 | $3,699 | $17 |
| Amiodarone | 76 | $3,503 | $46 |
| Amlodipine Besylate | 301 | $3,428 | $11 |
| Hydralazine | 105 | $3,396 | $32 |
| Valsartan | 25 | $3,290 | $132 |
| Furosemide | 255 | $2,737 | $11 |
| Torsemide | 51 | $2,587 | $51 |
| Digoxin | 51 | $2,214 | $43 |
| Isosorbide Mononitrate Er | 45 | $1,912 | $42 |
| Bumetanide | 14 | $1,851 | $132 |
| Carvedilol | 107 | $1,621 | $15 |
| Spironolactone | 103 | $1,476 | $14 |
| Lisinopril | 148 | $1,397 | $9 |
| Bisoprolol | 11 | $971 | $88 |
| Clopidogrel | 69 | $895 | $13 |
| Hydrochlorothiazide | 92 | $657 | $7 |
| Pantoprazole | 21 | $642 | $31 |
| Metoprolol | 101 | $624 | $6 |
| Atenolol | 50 | $539 | $11 |
| Pravastatin | 36 | $509 | $14 |
| Nitroglycerin | 12 | $331 | $28 |
| Clonidine | 14 | $322 | $23 |
| Benazepril | 14 | $220 | $16 |
| Simvastatin | 14 | $150 | $11 |
| Losartan-Hydrochlorothiazide | 12 | $79 | $7 |
| Amoxicillin | 28 | $38 | $1 |
2020: 33 drugs
| Eliquis | 254 | $283,526 | $1,116 |
| Xarelto | 23 | $28,555 | $1,242 |
| Entresto | 19 | $20,322 | $1,070 |
| Metoprolol | 323 | $11,941 | $37 |
| Diltiazem 24hr Er (Cd) | 62 | $6,780 | $109 |
| Rosuvastatin | 131 | $5,542 | $42 |
| Atorvastatin | 218 | $3,682 | $17 |
| Ezetimibe | 50 | $3,117 | $62 |
| Isosorbide Dinitrate | 15 | $2,839 | $189 |
| Amiodarone | 59 | $2,821 | $48 |
| Flecainide Acetate | 26 | $2,771 | $107 |
| Losartan | 147 | $2,608 | $18 |
| Hydralazine | 63 | $2,300 | $37 |
| Amlodipine Besylate | 227 | $2,228 | $10 |
| Valsartan | 17 | $1,919 | $113 |
| Furosemide | 167 | $1,771 | $11 |
| Digoxin | 34 | $1,514 | $45 |
| Isosorbide Mononitrate Er | 38 | $1,292 | $34 |
| Torsemide | 27 | $1,213 | $45 |
| Carvedilol | 74 | $924 | $12 |
| Clopidogrel | 51 | $911 | $18 |
| Lisinopril | 110 | $879 | $8 |
| Spironolactone | 71 | $834 | $12 |
| Hydrochlorothiazide | 71 | $778 | $11 |
| Cartia Xt | 13 | $600 | $46 |
| Pravastatin | 25 | $526 | $21 |
| Metoprolol | 59 | $454 | $8 |
| Atenolol | 45 | $446 | $10 |
| Nitroglycerin | 22 | $372 | $17 |
| Pantoprazole | 14 | $352 | $25 |
| Simvastatin | 23 | $244 | $11 |
| Warfarin | 12 | $216 | $18 |
| Benazepril | 16 | $123 | $8 |
2019: 27 drugs
| Eliquis | 129 | $112,828 | $875 |
| Metoprolol | 194 | $6,542 | $34 |
| Rosuvastatin | 57 | $4,407 | $77 |
| Diltiazem 24hr Er (Cd) | 40 | $3,871 | $97 |
| Atorvastatin | 95 | $2,212 | $23 |
| Flecainide Acetate | 22 | $1,963 | $89 |
| Losartan | 93 | $1,424 | $15 |
| Amlodipine Besylate | 128 | $1,291 | $10 |
| Ezetimibe | 15 | $1,133 | $76 |
| Furosemide | 122 | $962 | $8 |
| Digoxin | 16 | $958 | $60 |
| Bumetanide | 12 | $701 | $58 |
| Hydralazine | 27 | $684 | $25 |
| Metoprolol | 63 | $666 | $11 |
| Lisinopril | 81 | $621 | $8 |
| Isosorbide Mononitrate Er | 23 | $617 | $27 |
| Cartia Xt | 25 | $598 | $24 |
| Hydrochlorothiazide | 44 | $597 | $14 |
| Amiodarone | 16 | $529 | $33 |
| Clopidogrel | 25 | $517 | $21 |
| Carvedilol | 39 | $420 | $11 |
| Potassium Chloride | 14 | $376 | $27 |
| Pantoprazole | 15 | $367 | $24 |
| Spironolactone | 23 | $354 | $15 |
| Atenolol | 26 | $308 | $12 |
| Valsartan | 15 | $190 | $13 |
| Nitroglycerin | 11 | $155 | $14 |
2018: 17 drugs
| Eliquis | 48 | $31,523 | $657 |
| Metoprolol | 64 | $1,844 | $29 |
| Atorvastatin | 70 | $1,575 | $22 |
| Rosuvastatin | 28 | $1,494 | $53 |
| Hydralazine | 27 | $664 | $25 |
| Flecainide Acetate | 15 | $610 | $41 |
| Metoprolol | 59 | $442 | $7 |
| Clopidogrel | 22 | $350 | $16 |
| Amlodipine Besylate | 51 | $337 | $7 |
| Isosorbide Mononitrate Er | 14 | $326 | $23 |
| Furosemide | 50 | $280 | $6 |
| Carvedilol | 19 | $219 | $12 |
| Hydrochlorothiazide | 17 | $201 | $12 |
| Nitroglycerin | 14 | $192 | $14 |
| Losartan | 18 | $145 | $8 |
| Lisinopril | 24 | $137 | $6 |
| Spironolactone | 19 | $133 | $7 |
Money from drug and device companies
$162 in 2024
| 2024 | 1 | 1 | None | $162 |
| 2023 | 1 | 1 | None | $129 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Heartflow | Ffrct | $162 | 1 payment
|
See the published payment
| Heartflow | Meals · 2024-05-28 | Ffrct | $162 |
See earlier years (2023)
2023: $129
| Boston Scientific | Watchman Flx | $129 | 1 payment
|
Professional record
- NPI
- 1578889960
- Licence
- CA A119670California A119670: Current · expires 2028-01-31
- Group
- Sutter Bay Medical Foundation · Physician Services at El Camino Hospital
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 2350 W El Camino Real Fl 2, Mountain View, CA, 94040
- NPI first listed
- 2010-04-12
- NPI last updated
- 2022-09-21
- NPI record certified
- 2022-09-21
This is when the NPI record was last certified, not a medical board exam.